Natco Pharma Limited has informed the Exchange regarding Appointment of Mr Amit Parekh as Chief Financial Officer of the company w.e.f. February 13, 2026.
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved in line with Nifty Smallcap 250 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Natco Pharma announced that its current CFO, Mr. S.V.V.N. Appa Rao, retired (superannuated) at the close of business on 12th February 2026. Mr. Amit Parekh, who already serves as Executive Vice President – Finance and Accounts at Natco, was appointed as the new CFO effective 13th February 2026. Mr. Parekh brings over 23 years of experience and was previously associated with Dr. Reddy's Laboratories in senior finance roles. Additionally, Mr. Kalakuntla Srinivas Rao was appointed as Executive Vice President – Pharma Division, bringing 25+ years of experience from MSN Laboratories and Lupin. The CFO transition is an internal promotion, suggesting planned succession and continuity in financial leadership.
The change appears to be a planned, orderly succession with the new CFO being promoted internally from the existing finance team, which should ensure continuity in financial reporting and strategy. Shareholders are unlikely to see material disruption; the impact is neutral to mildly positive given the appointee's strong pharma sector experience.